Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve clinical responses to improve the lives of patients with cancer. Co. is developing a number of tumor-selective, agents through various stages of development. Co.'s product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody and XTX202, an interleukin 2 therapy. Co. is also developing its tumor-selective IL-12 product candidate, XTX301 and is focusing on preclinical studies for its tumor-selective IL-15 product candidate, XTX401. Co. has worldwide development and commercialization rights to all of its product candidates. We show 3 historical shares outstanding datapoints in our coverage of XLO's shares outstanding history.
Understanding the changing numbers of XLO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XLO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XLO by allowing them to research XLO shares outstanding history
as well as any other stock in our coverage universe. |
Free XLO Email Alerts:
Video: Shares Outstanding Importance
